OBJECTIVE: To determine the predictive value of shared epitope alleles for response to treatment in patients with rheumatoid arthritis. METHODS: Patients from our previously published triple DMARD study were tested for the presence of shared epitope alleles (DRB1 *0401, 0404/0408, 0405, 0101, 1001, and 1402). Patients who were shared epitope positive were then compared with those who were negative to see if there was a differential effect on therapeutic response. RESULTS: Shared epitope positive patients were much more likely to achieve a 50% response if treated with methotrexate-sulphasalazine-hydroxychloroquine compared with methotrexate alone (94% responders versus 32%, p < 0.0001). In contrast shared epitope negative patients did equally well regardless of treatment (88% responders for methotrexate-sulphasalazine-hydroxychloroquine versus 83% for methotrexate). Additionally, a trend toward an inverse relation of the gene dose was seen for response to methotrexate treatment (p = 0.05). CONCLUSIONS: These data suggest that determining shared epitope status may provide clinical information useful in selecting among treatment options.
OBJECTIVE: To determine the predictive value of shared epitope alleles for response to treatment in patients with rheumatoid arthritis. METHODS:Patients from our previously published triple DMARD study were tested for the presence of shared epitope alleles (DRB1 *0401, 0404/0408, 0405, 0101, 1001, and 1402). Patients who were shared epitope positive were then compared with those who were negative to see if there was a differential effect on therapeutic response. RESULTS: Shared epitope positive patients were much more likely to achieve a 50% response if treated with methotrexate-sulphasalazine-hydroxychloroquine compared with methotrexate alone (94% responders versus 32%, p < 0.0001). In contrast shared epitope negative patients did equally well regardless of treatment (88% responders for methotrexate-sulphasalazine-hydroxychloroquine versus 83% for methotrexate). Additionally, a trend toward an inverse relation of the gene dose was seen for response to methotrexate treatment (p = 0.05). CONCLUSIONS: These data suggest that determining shared epitope status may provide clinical information useful in selecting among treatment options.
Authors: N J Leech; A E Kitabchi; L K Gaur; W A Hagopian; J Hansen; G A Burghen; J P Palmer; G T Nepom Journal: Autoimmunity Date: 1995 Impact factor: 2.815
Authors: F Wolfe; D M Mitchell; J T Sibley; J F Fries; D A Bloch; C A Williams; P W Spitz; M Haga; S M Kleinheksel; M A Cathey Journal: Arthritis Rheum Date: 1994-04
Authors: J R O'Dell; C E Haire; N Erikson; W Drymalski; W Palmer; P J Eckhoff; V Garwood; P Maloley; L W Klassen; S Wees; H Klein; G F Moore Journal: N Engl J Med Date: 1996-05-16 Impact factor: 91.245
Authors: Jessica Wojciechowski; Michael D Wiese; Susanna M Proudman; David J R Foster; Richard N Upton Journal: Br J Clin Pharmacol Date: 2015-05 Impact factor: 4.335
Authors: Wenfeng Tan; Hui Wu; Jian Zhao; Lezlie A Derber; David M Lee; Nancy A Shadick; Doyt L Conn; Edwin A Smith; Vivian H Gersuk; Gerald T Nepom; Larry W Moreland; Daniel E Furst; Susan D Thompson; Beth L Jonas; V Michael Holers; David N Glass; Pojen P Chen; S Louis Bridges; Michael E Weinblatt; Harold E Paulus; Betty P Tsao Journal: Arthritis Rheum Date: 2010-10
Authors: H Marotte; B Pallot-Prades; L Grange; J Tebib; P Gaudin; C Alexandre; J L Blond; M A Cazalis; B Mougin; P Miossec Journal: Ann Rheum Dis Date: 2005-08-11 Impact factor: 19.103
Authors: Hala M Raslan; Hanaa R Attia; Iman Salama; Mona Hamed Ibrahim; Eman Mahmoud Hassan; Mohamed S El Hussieny; Manal M El Menyawi; Khalda S Amr Journal: Rheumatol Int Date: 2016-06-20 Impact factor: 2.631